Report Overview

The Global Hunter syndrome drugs market size stood at USD 0.94 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Hunter syndrome is a genetically inherited disease and caused due to a particular defect in the gene formation. The defect results in lack of production of major enzymes that enables a breakdown of sugary molecules in diet, termed as mucopolysaccharides. These get formed in the body of patient and leads into damage of vital organs. As a part of treatment, the patients are dosed with frequent replacements with enzymes that are responsible for synthesis of mucopolysaccharides to prevent their accumulation



Market Drivers

Increase in number of patients suffering from mucopolysaccharidosis II is likely to fuel the market growth during the forecast period. In addition, rise in the healthcare expenses and government initiatives for betterment of health. Increased R&D activities to counter hunter syndrome in children is more likely to propel the market demand during the forecast period